Surmodics Announces Launch of Preside™ Medical Device Coating Technology, Providing Industry-Leading Lubricity and Durability to a Broader Range of Complex Device Applications
October 31 2023 - 7:30AM
Business Wire
Surmodics, Inc. (NASDAQ: SRDX), the global leader in medical
device coating technologies, announced the commercial launch of its
most advanced hydrophilic medical device coating technology,
Preside™ hydrophilic coatings.
Preside hydrophilic coatings complement Surmodics’ existing
Serene hydrophilic coatings by providing customers with a unique
low-friction and low-particulate generation coating to further
enhance distal access for neurovascular applications, as well as
improve crossing for challenging coronary lesions or chronic total
occlusions.
Preside hydrophilic coatings are specifically formulated to meet
the challenge of achieving the right balance of enhanced lubricity
(reduction in friction) and excellent coating durability (resulting
in low particulates) for the next-generation of Neurovascular,
Coronary and Peripheral vascular devices. Surmodics’ Preside
hydrophilic coatings allow customers to leverage their existing
coating processes resulting in easy implementation in a
manufacturing environment.
“Hydrophilic coatings are an essential feature to help medical
devices access and navigate tortuous vascular pathways, allowing
physicians to reach distal treatment sites for improved therapeutic
outcomes,” said Charlie Olson, Senior Vice President, and President
of Surmodics’ Medical Device Coatings business. “We are pleased to
secure the first 510(k) device clearance that leverages this new
technology. Our Preside hydrophilic coatings strengthen our
existing portfolio and sets a new performance standard for the
industry, and the medical device manufacturers we serve.”
About Preside™ Hydrophilic Coatings
Surmodics’ Preside™ hydrophilic coatings combine a unique
industry-leading lubricity and durability, including dramatically
improved particulate reduction to address today’s increasing
regulatory requirements.
Preside hydrophilic coatings successfully bond to a wide variety
of substrates present on today’s market-leading neurovascular,
coronary and peripheral catheters. Preside hydrophilic coatings are
applied using Surmodics’ patented Photolink™ UV curing process,
which covalently bonds surface treatments to substrates at ambient
temperature. This flexible technology can easily be incorporated
into existing manufacturing processes and can markedly reduce
production time and reagent costs compared to both thermal-curing
and alternative UV-based chemistries and processes.
Surmodics’ chemistries have a proven regulatory record with
leading coronary, peripheral, neurovascular and structural heart
device applications. Surmodics collaborates with licensed customers
to satisfy coating product performance specifications, while
navigating through regulatory requirements to accelerate our
customer’s speed to market.
About Surmodics, Inc.
Surmodics is a leading provider of performance coating
technologies for intravascular medical devices and chemical and
biological components for in vitro diagnostic immunoassay tests and
microarrays. Surmodics also develops and commercializes highly
differentiated vascular intervention medical devices that are
designed to address unmet clinical needs and engineered to the most
demanding requirements. This key growth strategy leverages the
combination of the company’s expertise in proprietary surface
modification and drug-delivery coating technologies, along with its
device design, development, and manufacturing capabilities. The
company’s mission is to improve the detection and treatment of
disease. Surmodics is headquartered in Eden Prairie, Minnesota. For
more information, visit www.surmodics.com. The content of
Surmodics’ website is not part of this press release or part of any
filings that the company makes with the Securities and Exchange
Commission.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231031660711/en/
Surmodics Investor Inquiries: Jack Powell, Investor Relations
ir@surmodics.com
SurModics (NASDAQ:SRDX)
Historical Stock Chart
From Apr 2024 to May 2024
SurModics (NASDAQ:SRDX)
Historical Stock Chart
From May 2023 to May 2024